Clofarabine 20mg Injection Cfara

Trade Name: Cfara

Manufacturer: Zydus Cadila

Presentation: Injection

Strength: 20mg

What is the purpose of clofarabine?

Clofarabine is a medicine used to treat acute lymphoblastic leukaemia (ALL; a kind of white blood cell cancer) in children and young adults aged 1 to 21 who have already received at least two other treatments. Clofarabine belongs to the class of medicines known as purine nucleoside antimetabolites.

What does Cfara Injection entail?

Clofarabine Injection is used to treat severe lymphoblastic leukaemia in children, adolescents, and young adults (ALL). It is used when previous medications have failed or stopped working. It could also be used to treat another ailment.

What is the purpose of Cfara Clofarabine 20mg Injection?

Cfara Injection is also used in combination with other drugs as part of combined chemotherapy. It is administered as an infusion into a vein under the supervision of a physician. Your PCP will determine which component is most necessary and how often you should take it. This will depend on the reason you’re being treated and may alter over time. You should take it exactly as directed by your primary care physician. If you take too much or misinterpret it, you can get serious side effects. It may take a few weeks or months for you to notice or feel the benefits, but don’t stop taking it until your doctor tells you to.

Clofarabine 20mg Injection side effects include:

Sickness, retching, runs, migraines, and rash are among the most well-known side effects of this medicine. This drug may reduce the number of platelets in your blood (red blood and white platelets fall), increasing your vulnerability to illnesses. Standard blood tests are required to examine your platelets, as well as your heart, liver, and blood uric corrosive levels.

Clofarabine, also known as Clolar in the United States and Canada, is a purine nucleoside antimetabolite. Evoltra is the brand name for the product in Europe and Australia/New Zealand. It has been approved by the FDA to treat relapsed or refractory acute lymphoblastic leukaemia (ALL) in children who have failed at least two prior treatments. There have been some effective studies in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML). Its efficacy in treating different malignancies is being evaluated in ongoing research. Read more

We are a Global Wholesaler and Exporter from India and Operate in more than 5 Countries like UAE, Oman, Qatar, Saudi, Myanmar, etc. If you are looking for a Product or Brand To Click here.